Schultheiss HP, Fairweather D, Caforio ALP, et al. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019;5:32.

Article  PubMed  PubMed Central  Google Scholar 

McDonagh TA, Metra M, Adamo M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;2021:3599–726.

Article  Google Scholar 

Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43:3997–4126.

Article  PubMed  Google Scholar 

Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.

Article  CAS  PubMed  Google Scholar 

Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453–8.

Article  PubMed  Google Scholar 

Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–8.

Article  CAS  PubMed  Google Scholar 

Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol. 2003;41:1707–12.

Article  PubMed  Google Scholar 

Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221–30.

Article  PubMed  Google Scholar 

Shen L, Jhund PS, Petrie MC, et al. Declining risk of sudden death in heart failure. N Engl J Med. 2017;377:41–51.

Article  PubMed  Google Scholar 

Schrage B, Uijl A, Benson L, et al. Association between use of primary-prevention implantable cardioverter-defibrillators and mortality in patients with heart failure: a prospective propensity score-matched analysis from the Swedish Heart Failure Registry. Circulation. 2019;140:1530–9.

Article  PubMed  Google Scholar 

Zabel M, Willems R, Lubinski A, et al. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J. 2020;41:3437–47.

Article  PubMed  PubMed Central  Google Scholar 

Verstraelen TE, van Barreveld M, van Dessel P, et al. Development and external validation of prediction models to predict implantable cardioverter-defibrillator efficacy in primary prevention of sudden cardiac death. Europace. 2021;23:887–97.

Article  PubMed  PubMed Central  Google Scholar 

Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396:819–29.

Article  PubMed  Google Scholar 

Huizar JF, Ellenbogen KA, Tan AY, Kaszala K. Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2328–44.

Article  PubMed  PubMed Central  Google Scholar 

Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;2021:373–498.

Google Scholar 

Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, et al. Out-of-hospital cardiac arrest—the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J. 2003;24:1204–9.

Article  PubMed  Google Scholar 

Anderson KP, Walker R, Urie P, et al. Myocardial electrical propagation in patients with idiopathic dilated cardiomyopathy. J Clin Invest. 1993;92:122–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Becker MAJ, Cornel JH, van de Ven PM, et al. The prognostic value of late gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy: a review and meta-analysis. JACC Cardiovasc Imaging. 2018;11:1274–84.

Article  PubMed  Google Scholar 

Klem I, Klein M, Khan M, et al. Relationship of LVEF and myocardial scar to long-term mortality risk and mode of death in patients with nonischemic cardiomyopathy. Circulation. 2021;143:1343–58.

Article  CAS  PubMed  Google Scholar 

Halliday BP, Gulati A, Ali A, et al. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. 2017;135:2106–15.

Article  PubMed  PubMed Central  Google Scholar 

Di Marco A, Brown PF, Bradley J, et al. Improved risk stratification for ventricular arrhythmias and sudden death in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2021;77:2890–905.

Article  PubMed  Google Scholar 

Rahimtoola SH, Dilsizian V, Kramer CM, et al. Chronic ischemic left ventricular dysfunction from pathophysiology to imaging and its integration into clinical practice. JACC Cardiovasc Imag. 2008;1:536–55.

Akhtar M, Elliott PM. Risk stratification for sudden cardiac death in non-ischaemic dilated cardiomyopathy. Curr Cardiol Rep. 2019;21:155.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Zwaag PA, van Rijsingen IA, de Ruiter R, et al. Recurrent and founder mutations in the Netherlands-Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy. Neth Heart J. 2013;21:286–93.

Article  PubMed  PubMed Central  Google Scholar 

Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31:2715–26.

Article  PubMed  Google Scholar 

Escobar-Lopez L, Ochoa JP, Royuela A, et al. Clinical risk score to predict pathogenic genotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2022;80:1115–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verstraelen TE, van Lint FHM, Bosman LP, et al. Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction. Eur Heart J. 2021;42:2842–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol. 2012;59:493–500.

Article  PubMed  Google Scholar 

Wahbi K, Yaou BR, Gandjbakhch E, et al. Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation. 2019;140:293–302.

Article  CAS  PubMed  Google Scholar 

Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol. 2016;68:2440–51.

Article  CAS  PubMed  Google Scholar 

Gigli M, Stolfo D, Graw SL, et al. Phenotypic expression, natural history, and risk stratification of cardiomyopathy caused by filamin C truncating variants. Circulation. 2021;144:1600–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Authors/Task Force m, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.

Bilchick KC, Wang Y, Cheng A, et al. Seattle Heart Failure and Proportional Risk Models predict benefit from implantable cardioverter-defibrillators. J Am Coll Cardiol. 2017;69:2606–18.

Article  PubMed  PubMed Central  Google Scholar 

Elming MB, Nielsen JC, Haarbo J, et al. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation. 2017;136:1772–80.

Article  PubMed  Google Scholar 

Lee CS, Chien CV, Bidwell JT, et al. Comorbidity profiles and inpatient outcomes during hospitalization for heart failure: an analysis of the U.S. Nationwide inpatient sample. BMC Cardiovasc Disord. 2014;14:73.

Article  PubMed  PubMed Central  Google Scholar 

Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124:136–43.

Article  PubMed  PubMed Central  Google Scholar 

Ruwald AC, Vinther M, Gislason GH, et al. The impact of co-morbidity burden on appropriate implantable cardioverter defibrillator therapy and all-cause mortality: insight from Danish nationwide clinical registers. Eur J Heart Fail. 2017;19:377–86.

Article  PubMed  Google Scholar 

Steinberg BA, Al-Khatib SM, Edwards R, et al. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail. 2014;2:623–9.

Article  PubMed  PubMed Central  Google Scholar 

Barra S, Providencia R, Paiva L, et al. Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations. Europace. 2015;17:174–86.

Article  PubMed